SEC Form 4 · accession 0001127602-18-003917
CONMED Corp · CNMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luke A Pomilio
Other
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 2:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2018 | S | 18,023 | $63.3762 | D | 0 | D | |
| Common Stock | Feb 1, 2018 | M | 18,400 | $51.30 | A | 18,400 | D | |
| Common Stock | Feb 1, 2018 | F | 16,438 | $63.35 | D | 1,962 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sars (Stock Appreciation Rights)F2 | $51.30 | Feb 1, 2018 | M | 18,400 | D | — | Feb 27, 2025 | Common Stock | 18,400 | 27,600 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $63.88. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder.
- F2The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (20%) over a five year period.